美国于1984年通过一项法案,其中提到 第一个挑战成功的仿制药企能获得180天市场独占期,
in which no other generics maker can sell versions of the drug in question, as Ranbaxysupposedly won with Lipitor.
在此期间其他仿制药企不能贩售同一专利药的其他仿制药,就像兰伯西获得立普妥仿制药的生产权一样。
However, Pfizer is exploiting a loophole in the 1984 law, which lets it appoint a second,authorised copycatin this case, Watson, another American firm.
然而,辉瑞钻了这个法案的空子,它让第二家授权仿制药企业华生制药公司来仿制。
According to BernsteinResearch, under the deal between the two drugmakers Pfizer willreceive about 70% of Watson s revenues from its approved copy of Lipitor.
根据BernsteinResearch的分析,在此交易期间,华生公司获得立普妥的仿制权,辉瑞将获得华生公司年收入的70%。
More unusual, Pfizer has cut the price of its original version, and will keep marketing itvigorously.
更为不同的是,辉瑞将降低立普妥专利药的价格,并对其采取积极的营销策略。
So Ranbaxy faces not one, but two competitors.
所以说,兰伯西的对手是两个,而非一个。
【2015考研英语阅读制药企业悬念】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30